Buserelin acetate, a gonadotropin-releasing hormone agonist (GnRH agonist), is widely used as a therapeutic agent for myoma uteri (MU). We investigated the standardtreatments for MU before and after the introduction of buserelin therapy by questionnaire given to gynecologists and according to official statistics. Based on our study, an economic analysis (cost analysis) was made using a tree model. The results indicated that: 1) the standard treatment for MU underwent a change after buserelin therapy became available, and 2) the therapeutic cost per patient with MU increased by a factor of 1.1-1.2. Finally, we discuss the justifiability of this cost increment based on the opinions of gynecologists who returned the questionnaire.
